Fig. 1 · Structure

Documents & Downloads

ITD-1

Cat. No. A12924 CAS 1099644-42-4

TGF-β inhibitor

ITD-1 is a novel and highly selective TGFβ pathway inhibitor. ITD-1 molecule turns stem cells into heart cells.

In Stock

Publications for ITD-1

1 publication citing this product

  1. M. C. Wilkes, .et al. , Nat Commun, 2020, 11: 3344 PMID: 32620751

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

ITD-1 promotes cellular depletion of TGFBR2. Receptor-expression and rescue experiments linked this loss to proteasome activity, while overexpressed TGFBR1 was not reduced. These findings do not identify a direct binding target. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
HEK293 IC50 0.85 μM Inhibition of TGFbeta/Smad in TGFbeta-2/activin A-stimulated HEK293 cells preincubated for 2 hrs before stimulation measured after 20 to 22 hrs by firefly/renilla luciferase reporter assay [PMID: 25817775]
HEK-293T IC50 0.46 μM Inhibition of TGBR2 signaling in human HEK293T cells assessed as inhibition of SMAD activation after 2 to 22 hrs by dual Luciferase Assay [PMID: 23130626]
HEK-293T IC50 0.85 μM Inhibition of TGBR2 signaling in human HEK293T cells assessed as inhibition of SMAD activation after 2 to 22 hrs by dual Luciferase Assay [PMID: 23130626]
HEK-293T IC50 6.9 μM Inhibition of TGBR2 signaling in human HEK293T cells assessed as inhibition of SMAD activation after 2 to 22 hrs by dual Luciferase Assay [PMID: 23130626]

ITD-1 Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of ITD-1 from 2 published references. In vitro models include CGR8 mouse embryonic stem cells carrying a Myh6-GFP reporter.

ITD-1 In Vitro Studies

ITD-1 showed a timing-dependent effect in mouse embryonic stem cells: 5 μM treatment on differentiation days 3–5 promoted the cardiac Myh6-GFP readout, whereas days 1–3 treatment suppressed cardiogenesis. [1]

Cellular TGFBR2 depletion and proteasome-inhibitor rescue

Cell-based study · HEK293T receptor-expression and flow-cytometry assays; endogenous receptor confirmation in HEK293T, DLD1 and A549 cells [1]

ITD-1 lowered TGFBR2 abundance, including cell-surface receptor, while overexpressed TGFBR1 was not reduced. Proteasome inhibitors rescued the receptor-loss phenotype; chloroquine did not. This establishes a cellular degradation phenotype, not direct molecular binding.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TGFBR2 versus TGFBR1 protein abundanceQualitative immunoblot result TGFBR2 decreased; overexpressed TGFBR1 was not reduced[1]
TGFBR2-mCherry high/low cell ratioPharmacological rescue MG132 and bortezomib rescued ITD-1-induced receptor loss; chloroquine did not[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM ITD-1 in immunoblot and rescue experiments
Exposure duration
24 h for Figure 2A–D immunoblots; time course in Figure 2J; rescue inhibitors added 3 h after ITD-1
Method
Cell-culture treatment followed by western blotting or flow cytometry
Vehicle
DMSO control
Co-treatment
Mechanistic rescue controls: MG132 0.1 μM, bortezomib 5 nM, or chloroquine 10 μM (Figure 2K–L)
Reported limits
Supplemental antibody details and complete supplement not retrieved; exact rescue-assay harvest time is not specified in the main caption.
Methods and source locations

Compound reported in the paper: ITD-1; Compound label in the paper: ITD-1

Results apply to the reported ITD-1 material and model; they do not validate an Adooq lot or an isolated enantiomer.

Figure 2A–L and caption pp.246–247; receptor Results pp.243,245; Receptor Degradation Assays p.249

TGFBR2 versus TGFBR1 protein abundance: Western blotting, with ACTB for TGFBR2 or GAPD for TGFBR1 normalization — Figure 2A–F, pp.246–247; Results pp.243,245

TGFBR2-mCherry high/low cell ratio: Flow cytometry of TGFBR2-mCherry; DMSO and inhibitor controls shown — Figure 2K–L and caption p.247; Results p.245

Timing-dependent cardiomyocyte differentiation

Cell-based study · CGR8 mouse embryonic stem cells carrying a Myh6-GFP reporter [1]

A common 5 μM treatment gave opposite cardiac-reporter outcomes at different differentiation stages. Days 3–5 gave the strongest promotion, whereas days 1–3 suppressed cardiogenesis.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Day-10 Myh6-GFP signal across ITD-1 exposure windowsDirectional response versus DMSO Promotion was optimal on days 3–5; treatment on days 1–3 abolished cardiogenesis according to the Results text[1]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM
Exposure duration
Two-day exposure windows from days 1–3 through days 7–9; Myh6-GFP imaging at day 10
Method
ITD-1 exposure during mouse ESC differentiation; image-based Myh6-GFP quantification
Vehicle
DMSO
Reported limits
Complete supplemental culture formulation was not retrieved; no exact fold-change is extracted from the graph.
Methods and source locations

Compound reported in the paper: ITD-1; Compound label in the paper: ITD-1

Results apply to the reported ITD-1 material and model; they do not validate an Adooq lot or an isolated enantiomer.

Figure 1A–C and caption p.245; Results pp.242–243; ESC methods p.249; statistics p.251

Day-10 Myh6-GFP signal across ITD-1 exposure windows: Image analysis of Myh6-GFP, normalized to vehicle; representative fluorescence images — Figure 1B–C, caption p.245; Results pp.242–243

ITD-1 In Vivo Studies

In a local injury study in young D2-mdx mice, intramuscular ITD-1 reduced muscle degeneration and fibro-calcification. It did not increase muscle stem-cell numbers or regenerated myofibers, limiting interpretation as a regenerative treatment. [2]

Local ITD-1 reduces dystrophic muscle pathology without restoring myogenesis

Animal study · Young D2-mdx mice with experimentally injured tibialis anterior muscle; contralateral muscle control [2]

Local ITD-1 reduced tissue degeneration and fibro-calcification but did not increase Pax7-positive muscle stem cells or regenerated myofibers.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Degenerated area as a percentage of total muscle cross-sectional areaReported group-level percentages 55% in injury-only muscle; 26% in injury plus ITD-1 muscle[2]
Pax7-positive cells and regenerated myofiber readoutsLimiting result No increase in Pax7-labeled muscle stem-cell number or regenerated myofibers[2]
PDGFRα-positive, calcified and fibrotic tissue areasDirectional histological result Reduced PDGFRα-positive area, calcification and fibrosis[2]

Conditions shared by the study groups

Route
Intramuscular
Frequency
At injury and 2 and 4 days afterward
Treatment course
Three administrations; dissection at age 33 days (7 days after initial treatment)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Local ITD-1 versus contralateral injured muscle control
2000 ng ITD-1 per intramuscular administration
Contralateral tibialis anterior received the same injury without ITD-1; equal-volume saline was used for subsequent control injections.Reduced p-SMAD3-positive centrally nucleated fibers, degenerating area, PDGFRα-positive area, calcification and fibrosis; no increase in Pax7-positive cells or regenerated fibers.[2]
Local ITD-1 versus contralateral injured muscle control
Model: D2-mdx mice; tibialis anterior muscle, treatment begins at age 26 days
Reported limits: ITD-1 solvent/stock formulation and sex of the Figure 6 cohort are not explicitly stated in the read material; saline control does not establish drug formulation.
Methods and source locations

Compound reported in the paper: ITD-1; Compound label in the paper: ITD-1

Results apply to the reported ITD-1 material and model; they do not validate an Adooq lot or an isolated enantiomer.

Figure 6D–R and caption; corresponding Results; Methods Animals, ITD-1 dosing/control paragraph, histology and Statistics

Degenerated area as a percentage of total muscle cross-sectional area: Histological quantification; n=5 muscles with and n=5 without ITD-1 in Figure 6L; mean ± SD per Statistics; two-tailed nonparametric Mann–Whitney U test per caption — Results following Figure 6; Figure 6I,L and caption

Pax7-positive cells and regenerated myofiber readouts: Pax7 immunostaining and centrally nucleated/BrdU-positive fiber analysis; n=5 with and n=5 without ITD-1 — Figure 6G–K and caption; Results following Figure 6

PDGFRα-positive, calcified and fibrotic tissue areas: PDGFRα immunostaining (n=4 per condition); alizarin red and trichrome staining (n=5 per condition); mean ± SD — Figure 6M–R and caption; Statistics

Local ITD-1 versus contralateral injured muscle control · Figure 6D–R and caption; Methods ITD-1 dosing/control paragraph; Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1099644-42-4
Applications TGF-β inhibitor
Formula C27H29NO3
Molecular Weight 415.52
SMILES
O=C(C1=C(C)NC2=C(C(CC(C)(C)C2)=O)C1C3=CC=C(C4=CC=CC=C4)C=C3)OCC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 76 mg/mL (182.89 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

ITD-1 Research References

  1. [1] Willems E, Cabral-Teixeira J, Schade D, et al. Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell stem cell (2012). PMID: 22862949 DOI: 10.1016/j.stem.2012.04.025 Source material
  2. [2] Mázala DA, Novak JS, Hogarth MW, et al. TGF-β-driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model. JCI insight (2020). PMID: 32213706 DOI: 10.1172/jci.insight.135703 Source material

Publications

1 publication citing this product

  1. M. C. Wilkes, .et al. , Nat Commun, 2020, 11: 3344 PMID: 32620751

Added to your cart

View Cart Checkout
Loading...